Maximize target selection and validation in cancer research with the high-plex SomaScan® Assay
We look forward to meeting you at AACR 2024 in San Diego.
Join us at booth 3718 at AACR 2024 to share the most influential advances in cancer science and disease understanding
We’re honored to host a presentation on data from the European Prospective Investigation into Cancer and Nutrition (EPIC) by Marc Gunter and Karl Smith-Byrne, from Imperial College, London, and Oxford University. See details below.
Stop by Booth 3718 to talk through the presentation with our scientific team. And ask us how you can deepen your cancer research using high-plex protein profiling with the new SomaScan 11K Assay — enabling 11,000 protein measurements (HALF the genetically encoded human proteome) with unparalleled reproducibility and specificity.
Scroll down for full details.
SPOTLIGHT THEATER PRESENTATION
Discovering novel causes and biomarkers of cancer through high dimensional proteomics within a large-scale prospective cohort
European Prospective Investigation into Cancer and Nutrition (EPIC)
Sunday, April 7 | 1:30-2:30 p.m. | Location: Spotlight Theater E
Presenter: Marc Gunter, PhD
Cancer Epidemiology and Prevention Unit
School of Public Health
Imperial College, London
Presenter: Karl Smith-Byrne, PhD
Cancer Epidemiology Unit
Oxford Population Health
Oxford University
Prevention and early detection strategies for cancer are urgently needed; however, the causes of many cancers remain poorly defined, and there is a lack of validated biomarkers of cancer risk and progression.
To discover novel biomarkers of cancer and identify potential causal pathways, our esteemed speakers measured 7,000 aptamers using the SomaScan® 7K Assay in a case-cohort study of ~20,000 participants within the European Prospective Investigation into Cancer and Nutrition (EPIC). In this presentation, they will describe early insights from the study, including potential new biomarkers of specific cancers and mortality, as well as highlight common sets of predictive proteins across cancer types.
Presentation co-sponsored by SomaLogic and Agilent. Room capacity: 75. Seating is on a first-come, first-served basis. We encourage early arrival. Once the theater is full, we will have to turn away additional attendees. This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research (AACR(R)).
